

Mung bean nuclease cleavage pattern at a polypurine·polypyrimidine sequence upstream from the mouse metallothionein-I gene

Albino Bacolla^{1,*} and Felicia Y.-H. Wu^{1,2}

¹Department of Pharmacological Sciences, State University of New York at Stony Brook, Stony Brook, NY 11794, USA and ²Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan, RO China

Received November 8, 1990; Revised and Accepted March 6, 1991

EMBL accession no. X53530

ABSTRACT

Mung bean nuclease, an enzyme specific for single-stranded DNA, was used to probe a non-B DNA structure present in the mouse metallothionein-I gene. The region sensitive to the enzyme was constituted by a 128 base-pair long polypurine·polypyrimidine sequence located at 1.2-kb from the start of transcription. A detailed analysis of the mung bean nuclease cleavage pattern revealed that: (i) under conditions of supercoiling and low pH a triplex structure was formed, (ii) the triplex was flanked by a sequence with the potential of forming a Z-DNA structure, (iii) most of the enzymatic activity was localized at some of the junctions between double-stranded and triple-stranded DNA and at mismatches in the triplex, (iv) no unpaired bases were observed in the loop or outside the triplex, and (v) the triplex was present in more than one configuration.

INTRODUCTION

The association of polypurine with polypyrimidine sequences into triple-stranded structures has been studied for more than 30 years (1). It is known, in fact, that when complementary polypurines and polypyrimidines are present in a 1:2 ratio at low pH, the product is a three-stranded molecule in which the purine bases are simultaneously engaged in Watson-Crick and Hoogsteen hydrogen bonds (2-8). The characterization of these intermolecular structures has been achieved by means of different methods, including X-ray fiber diffraction (9-12), infrared spectroscopy (4-6), circular dichroism (13,14) and NMR (15-17). Recently, however, the ability of polypurine·polypyrimidine (polyR·polyY) sequences to form intramolecular triplexes has been observed under the conditions of low pH and negative supercoiling (18-28). Intramolecular triplexes are more complex than the intermolecular ones: they contain at least one internal loop and four junctions, two between triplex and loop, and two between triplex and vector sequences (Scheme 1b). Intramolecular triplexes have been studied so far

by enzymatic and chemical probes, since bases in a single-stranded configuration or at junctions have been shown to display hypersensitivity toward these probes. Chemical modification has been proven to be relatively nonspecific: bases outside the triplexes are also hyperreactive, and bases in the loop may retain their hyperreactivity upon release of supercoiling (20,22,24,26,29). Enzymatic probes have been poorly exploited, while biophysical methods have been impeded mostly by the requirement of supercoiling.

In this paper we describe the use of mung bean nuclease (*MBN*), an enzymatic probe, to study a long and heterogeneous polyR·polyY sequence upstream from the mouse metallothionein-I (mMT-I) gene. We chose this enzyme for several reasons: first, like S1 nuclease, it recognizes triplexes with high sensitivity; second, it is a milder enzyme than S1 nuclease (30) and third, it has been used at low temperature to specifically cleave single-stranded loops of hairpins (31). Our results showed that *MBN* activity was confined to the polyR·polyY sequence and that the bases outside and in the loop of the triplex were not in a single-stranded configuration. The specificity of the probe was exploited to derive a hydrogen bonding pattern for the triplex structure.

MATERIALS AND METHODS

DNA and biochemicals

Plasmid pBR-MT harbors a 3.8-kb *EcoRI-EcoRI* fragment containing the mMT-I gene and flanking sequences cloned in pBR322 (Fig. 1a). Phage M13mt1 was constructed as follows. Five μ g of plasmid pBR-MT was cleaved with *EcoRI* and *KpnI* and the purified DNA was incubated with 5 U of *Klenow* enzyme (Boehringer/Mannheim) for 5 min at 37°C, followed by 15 min at 23°C in the presence of 2.5 mM of the four deoxynucleoside triphosphates in order to make both ends blunt. The products were separated on agarose gel and the 1.2-kb fragment was recovered with DEAE paper (32). The vector DNA was prepared by dephosphorylating *SmaI*-cleaved M13mp18. Ligation, transformation and large scale DNA preparation were according to standard procedures (33-36). *E. coli* JM101 used to grow

* To whom correspondence should be addressed at Boehringer Ingelheim, MBL, PO Box 368, 90 East Ridge, Ridgefield, CT 06877, USA

phage DNA were maintained and grown on minimal media (37). A 1-kb DNA ladder was obtained from BRL. Restriction enzymes (New England Biolabs and Boehringer/Mannheim) were used according to the manufacturer's specifications in buffers prepared before each reaction. Radioactive nucleotides were from Amersham and most of the other chemicals from Fluka (MicroSelect grade when available).

MBN reactions and DNA labeling

DNA was stored at 0°C in 10 mM Tris-HCl (pH 8.0), 1 mM EDTA or 10 mM Tris-HCl (pH 8.0), 50 mM NaCl and 1 mM EDTA. DNA was first ethanol precipitated to avoid the contribution of Tris-HCl to the final pH, then resuspended in H₂O and freshly made MBN buffer (final concentration: 30 mM sodium-acetate (pH 4.5), 50 mM NaCl, 1 mM zinc-acetate and 5% glycerol). When high concentrations of MBN were used the glycerol content of the enzyme storage buffer was taken into account. The dilution buffer for MBN was 10 mM sodium-acetate (pH 5.0), 1 mM dithiothreitol, 0.1 mM zinc-acetate, and 0.001% Triton X-100. Starting from DNA banding in the CsCl gradient the contamination with metals was kept minimum (25,38). The DNA samples were allowed to equilibrate on ice for 15–20 min and MBN (Pharmacia) was added. The reactions were carried out on ice for the period indicated and stopped by the addition of Tris base and EDTA to the final concentrations of 70–90 mM and 40–45 mM, respectively. The DNA was finally phenol/chloroform extracted and ethanol precipitated.

To locate the MBN cutting sites in the polyR·polyY sequence, RF M13mt1 was cleaved with 10, 100, or 800 U of MBN for 10 min and digested with *EcoNI* or *AlwNI* (Fig. 3). The *EcoNI* site was labeled with *Klenow* and [α^{32} P]dTTP; the 3' ends of the *AlwNI* cleaved sample were labeled with terminal deoxynucleotidyl transferase (*TdT*) (Pharmacia) and [α^{32} P]ddATP. The products were separated on native 6% polyacrylamide gel (0.3×40 cm) after removal of the unincorporated radioactivity by Sephadex G-50 minicolumn.

To specifically locate the MBN cutting sites on both strands of the polyR·polyY sequence, RF M13mt1 was cleaved with 800 U of enzyme for 10 min. The 3' ends were labeled with *TdT* and [α^{32} P]ddATP; the 5' ends were labeled with T4 polynucleotide kinase and [γ^{32} P]dATP. After removing the unincorporated radioactivity the DNA was cleaved with *EcoNI* or *AlwNI* and the products were separated on a native 6% polyacrylamide gel, recovered and rerun on a 8% sequencing gel. A radioactive 1-kb ladder was prepared by filling-in the 3' ends with *Klenow*, using [α^{32} P]dCTP. After labeling, this marker was 8-bp longer than what was specified by the manufacturer.

Sequencing

Sequencing was carried out on either single-stranded M13mt1 or RF M13mt1 and pBR-MT by the primer extension method. Commercial (Pharmacia) or synthetic HPLC-purified primers were used in an overall walking primer strategy.

RESULTS

Characteristics of RF M13mt1

Phage M13mt1 contains a 1.2-kb fragment from the upstream region of the mMT-I gene cloned in the *SmaI* site of M13mp18 (Fig. 1). The 12 clones tested carried the insert in the same orientation. The transcribed messenger for the disrupted α -peptide




Fig. 1. Map of (a) plasmid pBR-MT and (b) phage M13mt1. Thin line: vector DNA; rectangles: mMT-I sequences. The boxed *SmaI/KpnI* and *SmaI/EcoRI* show the orientation of the *EcoRI-KpnI* fragment of the mMT-I into the *SmaI* site of M13mp18. The restriction sites flanking the polylinker are indicated.




Fig. 2. Agarose gel electrophoretic pattern of MBN activity on RF M13mt1. Lanes 1 and 18: 1-kb DNA ladder (bands from 3- to 12-kb are shown); lane 2: native supercoiled M13mt1, nicked DNA migrates above 12-kb; lanes 3–7, 8–12, and 13–17: 10, 100, and 800 U, respectively, of MBN for 10, 20, 30, 60, and 120 min. The reactions were performed at 0–4°C.

bore the sequence of the non-coding strand of the cloned mMT-I fragment (Fig. 1b). The repaired *EcoRI* site of the mMT-I fragment was located toward the hybridization site of the universal direct sequencing primer of M13mp18. The bias observed in cloning fragments containing asymmetric sequences seems to be a relatively common event (39). We did not investigate this observation any further.

MBN activity on RF M13mt1

When supercoiled pBR-MT and RF M13mt1 were incubated with MBN, the DNA was readily converted to the circular form and, at a lower rate, to the linear one. Preliminary experiments carried out on pBR-MT and RF M13mt1 located the MBN sensitive region between the *EcoRI* and the *KpnI* sites of the mMT-I gene, at about 1.2-kb from the start of transcription (Fig. 1a). Further experiments located the MBN sensitive region in a polyR·polyY sequence. This activity was dependent on supercoiling (data not

```

-1774 AATTCTGGTTTTTTTGTGTTTGGTTTTGGTTTTGGTTTTGGTTTTTCGA
      GACAGGGTTTCTATATAGCCCTAGCTGTCTGGAACCTCACTTGTGTA
-1674 CCAGGCTGGCCTCGAACTCAGAAATCCGCCCTGCCTCCTGAGTGC
      TGGGATCAAGGGGTGGCCACCAACACCCGGCTGTTTTTTTTTTTTT
-1574 TTTTAATCTTAACTCACTTCTTATTAACCTTTGAAATAGGATCTCATT
      GTGTGGCCCTGGCTGGCCTGAATTTGACAGAGATCATCTGCCTGACT
-1474 TCTAAGAGCTGAGATTAAGAGACTACCTAAGGCAAGAATTAACGTAT
      AGATAAAGACTCAGTTCCAAATGAAGTTTTTTTTTGGATCTTCCACGC
-1374 AGAGGGTATTGCTGTGTGCTCTCCTCAAGAGGAAATATCCGGAGGAAG
      AGAAACCCCTGGTAAATATTATACCAAAACCAAGTGGGTGATAATAG
-1274 AAAGACACTGTATCTAAACCACTCAAGGAGGAGGAGGAGGAGGAGG
      GGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG
-1174 GAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG
      GAAAGTGTGTGTGGGGGGGGGAGTGCATAGCCAGCACCTGGTGCTT
-1074 TCTCTGCCTACAGATGAACCTTGTACAGAATCACAGCAAGAGAAGCTGGA
      CAAATACAGGAGCGTTAGTGCCAGGAGTGCTGGTTCACAGCCGTTGTAC
- 974 TACTGACTGGATATATGGCCGGGCAAGTCACTGAACCTCTGAATCCTCT
      GTCCTTGTGTGTAATAAGAAATTCATCTCTATAGGTATTAATAGAGA
- 874 AATTGGTTAACTCCTGGTTCTGGCATAATAGACATATTGCTGGTGGTG
      TTCTACCACAGTTAAGCAAAAACCTGCCAAAGTCGTATAGCTCAGAAGT
- 774 GATGGTATGCATGAGCCAACAGTGTAGCTGTTCTTGGCCAGGACACAA
      GGCCCTGCCTGACAGCAGACTCTAATGTTACTCAAATCAGAAGCATTAAA
- 674 AAAAAAAGAAAGAAAGAAATAGCTGACTTTATTTTTTATCTAATGACG
      TCCCCACCTAAAATGATCTCTCTGGAGGGAGGTTACCTTGGTTTTTAA
- 574 CCAGCCTGGAGTAGAGCAGATGGGTTAAGGTGAGTGACCCCTCAGCCCTG
      GACATTCTTAGATGAGCCCTCAGGAGTAGAGAATAATGTTGAGATGAG
- 474 TTCTGTTGGCTAAAATAATCAAGGCTAGCTCTTATAAAAGTCTCCTCT
      TCTCTAGCTTCGATCCAGAGAGACCTGGGGGAGCTGGTCTGCTGCTC
- 374 AGGAACTCCAGGAAAGAGAAGCTGAGGTTACCACGCTGCCAATGGGTTT
      ACGGAGATAGCTGGCTTCCGGGGTGGTTCTC (-292)

```

Fig. 3. Sequence of the 5' region of the mMT-I gene. The location of three relevant restriction sites is underlined. The underlined *nt* from -300 to -292 overlap with a published sequence (40), to which the numbers in italic refer. The 128-bp long polyR·polyY is shown in boldface characters.

shown). We performed all of the subsequent experiments with *MBN* at $0-4^{\circ}\text{C}$. A time course of *MBN* activity on RF M13mt1 at this temperature is shown in Fig. 2. With each enzyme concentration used, most of the linear DNA product was detected within the first 10 min of incubation (lanes 3, 8 and 13). Increasing amounts of linear DNA were accumulated at times greater than 10 min, in part as a result of nonspecific cleavage of the nicked DNA. When 800 U of enzyme were used, some degradation of the linearized DNA was already seen after 10 min (lane 13).

Sequence of the 5' flanking region of the mMT-I gene

The sequence of the mMT-I promoter up to nucleotide (*nt*) -300 from the start of transcription has already been reported (40). We extended the sequencing to the *EcoRI* site at *nt* -1775 in order to encompass the polyR·polyY region. The sequence (Fig. 3) starts at the underlined A of the GAATTC *EcoRI* restriction site (*nt* -1774) and it overlaps from *nt* -300 to -292 with the reported sequence (40). The position of the restriction site for *EcoNI* and *AlwNI*, used in subsequent experiments, is underlined. The polyR·polyY stretch responsible for the sensitivity to *MBN* is shown in bold letters. This sequence was 128-bp long, spanning from *nt* -1148 to -1221 , and it was flanked at the 3' end by a $(\text{TG})_5$ and a $(\text{G})_9$. In Figs. 6–7 and in Scheme 2 only this polyR·polyY sequence, numbered from 1 to 128 shall be reported. Sequencing of the complementary strand excluded the presence of mismatches, at least in the polyR·polyY region. Neither the ability of the $(\text{TG})_5$ to attain a Z-DNA conformation nor the sensitivity of the $(\text{G})_9$ to endonuclease-G (41) was examined.

High resolution mapping of the *MBN* cleavage in the polyR·polyY sequence

RF M13mt1 was incubated with 10, 100, or 800 U of *MBN* for 10 min. Each sample was divided into two aliquots; one was cut with *EcoNI*, the other with *AlwNI*. The *EcoNI* site was filled-in with *Klenow* and $[\alpha^{32}\text{P}]\text{dTTP}$, the 3' ends of the *AlwNI* cleaved sample were labeled with *TdT* and $[\alpha^{32}\text{P}]\text{ddATP}$. The purified DNA was run on a native 6% polyacrylamide gel. The result



Fig. 4. Native PAGE of the *MBN* cleavage pattern on RF M13mt1. Lanes 1 and 15: *AluI*-cleaved pBR322; lanes 2 and 14: 1-kb DNA ladder (only the length of these fragments is reported); lanes 3–4: cleavage with *EcoNI* + *AlwNI*; lanes 5–7: 10, 100, or 800 U of *MBN*; lanes 8–10: 10, 100, or 800 U of *MBN* and cleavage with *EcoNI*; lanes 11–13: 10, 100, or 800 U of *MBN* and cleavage with *AlwNI*. Incubations with *MBN* were for 10 min at $0-4^{\circ}\text{C}$. RE: restriction enzyme(s).

is shown in Fig. 4, lanes 8–13. In lanes 5–7 the restrictions were omitted to verify whether *MBN* alone would release short fragments. Incubation with *MBN* gave rise to a smear whose size decreased at higher enzyme concentrations (lanes 5–13). After





Fig. 5. Native PAGE of the *MBN* cleavage pattern on both strands of RF M13mt1: 800 U of *MBN* for 10 min at 0–4°C were used. Lane 1: *AluI*-cleaved pBR322; lane 2: *MBN* and 3' end-labeling; lane 3: *MBN* and 5' end-labeling; lane 4: *MBN*, 3' end-labeling (pyr. strand) and cleavage with *AlwNI* = A3y fragments; lane 5: *MBN*, 5' end-labeling (pur. strand) and cleavage with *AlwNI* = A5r fragments; lane 6: *MBN*, 3' end-labeling (pur. strand) and cleavage with *EcoNI* = E3r fragments; lane 7: *MBN*, 5' end-labeling (pyr. strand) and cleavage with *EcoNI* = E5y fragments. L: end-labeling.

MBN, the two restrictions released a set of well defined fragments shorter than the full length *EcoNI*-*AlwNI* (compare lanes 8–13 with 3–4). These fragments were resistant to 800 U of *MBN*. As expected from Fig. 2 (lanes 3, 8 and 13), the amount of product was proportional to the *MBN* concentration used (compare the intensity of the bands with the radioactivity at the top of the gel). Some of the shorter fragments were not seen with 10 U of enzyme (compare lane 11 with lanes 12–13). We sequenced some of the bands and confirm that the termini were at the restriction site (data not shown).

In order to determine the specific location of nuclease activity on both strands of the polyR·polyY sequence, RF M13mt1 was incubated with 800 U of *MBN* for 10 min. The sample was divided into two aliquots. One was 3' end-labeled with *TdT* and [α - 32 P]ddATP, the other was 5' end-labeled with T4 polynucleotide kinase and [γ - 32 P]dATP. Both aliquots were further divided into two parts. One was digested with *EcoNI*, the other with *AlwNI*. Four sets of fragments were therefore obtained on a native 6% polyacrylamide gel (Fig. 5, lanes 4–7). The pattern obtained was very similar to the one in Fig. 4. The bands were designed as follows: labeling of the 3' end on the pyrimidine strand followed by *AlwNI* cleavage gave 1A3y to 13A3y; labeling of the 5' end on the purine strand followed by *AlwNI* cleavage gave 1A5r to 13A5r; labeling of the 3' end on the purine strand followed by *EcoNI* cleavage gave 1E3r to 7E3r and labeling of the 5' end on the pyrimidine strand followed by *EcoNI* cleavage gave 1E5y to 7E5y. Our assumption, as shown in Scheme 1a,b, was that the formation of an intramolecular triplex would be recognized by *MBN* at the site of the unpaired



Scheme 1. Scheme for the formation of an intramolecular triplex and *MBN* activity. (a) thick line: polypurines; thin line: polypyrimidines; vertical bars: Watson–Crick hydrogen bonds; (b) under supercoiling and low pH the polyR·polyY sequence forms a triplex where the 3' part of the purine strand (R) folds back and engages Hoogsteen hydrogen bonds with the pyrimidine strand (Y) running in a parallel orientation; (////): Watson–Crick hydrogen bonds in the triplex; (\\ \\ \\) Hoogsteen hydrogen bonds; 1–4: junctions between double-stranded and triple-stranded DNA; (c) *MBN* recognizes distortions in the DNA backbone and cleaves at junctions; the event in which *MBN* cleaves the R at junction 1 and both strands at junction 2 is considered; RE A: restriction site; after *MBN* cleavage the triplex is no longer sustained by supercoiling; (d) 3' end-labeling occurs on the R at junction 1, 5' end-labeling occurs on the Y at junction 2; cleavage 5' from the triplex with a restriction enzyme (RE A) releases a partially single-stranded fragment that can be purified by native PAGE; (e) the length of both strands of this fragment is determined by denaturing PAGE. This scheme corresponds in the text to the set of fragments produced by *EcoNI*. Another set is produced by *AlwNI*.

purines and at the junctions between double-stranded and triple-stranded DNA. In the event of a single cut on the purine strand at junction 1 and a double cut at junction 2 (Scheme 1c), the 3' and 5' ends of the fragment released by a restriction enzyme (RE A in Scheme 1c,d) would not be blunt. The pyrimidine strand would be longer than the purine one, and this difference could be measured on a denaturing gel after the fragment had been purified from a native gel. Fig. 6a,b shows the sequencing gel pattern of the forty fragments eluted from the native gel of Fig. 5. Taking into account the staggered end of the fragments at the restriction site and the addition of the ddATP during labeling, we located all of the bands in the polyR·polyY sequence. Abundant fragments in Fig. 5 (7A, 4A, 6E, 7E) also gave the most prominent bands in Fig 6a,b. Closed squares indicate these bands (Figs. 6 and 7). Likewise, quantitatively less abundant but significant bands (1A, 2E, 3E, 5E in Fig. 5) are denoted by open




Fig. 6. Sequencing gel of the forty fragments eluted from the native gel of Fig. 5; (a): bands eluted from the *EcoNI* cleaved sample (lanes 6–7 in Fig. 5); the 74-nt-long ladder in lanes 13–14 is indicated; (b): lanes 1–26, bands eluted from the *AlwNI* cleaved sample (lanes 4–5 in Fig. 5); lane 27: fragment 4aE5y from lane 7 of Fig. 5; (c): the polyR·polyY sequence is reported, where nt 1 corresponds to nt –1248 of Fig. 3. Due to the staggered ends at the *EcoNI* and *AlwNI* restriction site and to the addition of a ddATP during the 3' end-labeling, the correspondence between bands and numbering in (a) and (b) is only approximative. Closed squares denote the most prominent bands and their location on the polyR·polyY sequence; less intense bands are denoted by open squares; solid and dotted arrows (for closed and open squares) point toward the respective restriction site; underlined purines in (c) and short traits in (a) and (b) denote the 'consistently cut sites'.

squares. The name of these fragments is reported in Fig. 6c, where solid (for closed squares) and dotted (for open squares) arrows point toward the respective restriction site. In Fig. 7, the position of all of the significant *MBN* cleavages is reported as lower case letters.

'Consistently cut sites' on the purine strand

In Fig. 6a,b the purine lanes contained constant bands (denoted by short traits). We called these bands 'consistently cut sites' to indicate that in all of the fragments the DNA was regularly recognized at some position. In the latter gel this pattern was uniform for the first 7 fragments, while for the longer fragments the lower bands were very weak. When the 'consistently cut sites' were located in the polyR·polyY sequence they corresponded to A13, G14, A28, G29 (Fig. 6a), and to G118, A108, A106, G101, A99, G95, A91 (Fig. 6b), respectively (Fig. 6c, underlined purines). Other constant bands were also present (see for example at nt 70–72 in lanes 10, 12, 14 of Fig. 6a).

Fragments with an overhanging pyrimidine strand

In fragments 7E, 4E (Fig. 6a), 9A and 10A (Fig. 6b) the purine strand was considerably shorter than the pyrimidine one. These fragments are marked by a star in Fig. 7. In fragment 7E the purine gap started around A13–G14, two of the 'consistently cut sites'. The pyrimidine strand was cut at several nt, the more

distal of which corresponded to T88 (Figs. 7a and 6a, lanes 13–14). The abnormally slow migration of fragment 7E on the native gel was ascribed to its partial single-stranded character (compare fragments 6E and 7E in Figs. 5, 6a and 7a). Fragment 4E (Figs. 7a and 6a, lanes 7–8) had an overhanging pyrimidine strand whose terminus mapped at T49; the purine strand was mainly cut at the 'consistently cut sites' A28–G29. In fragments 9A–10A (Fig. 6b, lanes 17–20), the purine strand was predominantly cut at the more distal of the 'consistently cut site' (A91) while the pyrimidine strand was cut between C45 and T54 (Fig. 7b).

Shortest and longest fragments

After *MBN*, restriction with *AlwNI* gave consistently more bands than the one with *EcoNI*. The cleavages with *MBN* at the 3' end of the polyR·polyY sequence (compare the termini of fragments 6E, 7E with those of 1A, 2A, 3A in Fig. 7a,b) were not revealed by the restriction with *EcoNI*. The size of fragments 11A–13A closely matched with the length of fragment 1E (Fig. 7a,b).

DISCUSSION

Most of the studies conducted on cloned polyR·polyY sequences using chemical or enzymatic probes support the formation of triple-stranded DNA but few of them provide information on the

(A28) to A54. There are mismatches at positions 20/115 and 27, at *nt* around 40/75 and 51/64. According to Scheme 2a, fragment 7E (Figs. 6a and 7a) would be cut (at *nt* 87–90) at a junction between triple-stranded and double-stranded DNA and the simultaneous activity at A13–G14 would allow the 74 purines to comigrate in the native gel and appear as the ladder seen in Fig. 6a (lanes 13–14). This ladder would represent random cleavage at the single-stranded bases. A double cut across junction 1 *or* at loop b would give fragments 1E and 6E, respectively (Fig. 7a). The termini of 7A, a quantitatively well represented fragment, are located in Scheme 2a in a region where the triplex could be destabilized by extensive mismatches. Fragments 3E and 5E, which are abundant as well, would be related to *MBN* activity in the same region.

According to our interpretation, the main nuclease activity would be associated with perturbations in the triplex structure whereas cleavages on the single-stranded purines would be, comparatively, weaker. If this is true, it implies that a distortion in torsion angles of nucleotides at junctions or at mismatches in a triplex represents the most sensitive target for *MBN* activity. Sugar pucker flexibility plays a key role at the junctions between *B*- and *Z*- (46) as well as *A*- and *B*-DNA (47), while association of nuclease activity with highly distorted parameters in the DNA structure has been proposed (48). Scheme 2a seems to account for the observation that the termini of fragment 6E did not coincide with those of fragment 1A (Fig. 7a,b). *MBN* cleaved at both *nt* 87–88 and 118–119, but preferred pyrimidines 87–88 (compare lanes 7–8 with 1–2 in Fig. 6b). This occurrence, and the possibility of molecules being cut at both positions, could have prevented the accumulation of a product complementary to fragment 1A. In the absence of loop b (Scheme 2b), most of the 'consistently cut sites' would be located too far from the triplex to be recognized by *MBN*. In fragments 4E and 9A/10A the pyrimidine strand was cut between C45 and T55, with some preference around C50. These pyrimidines were weakly recognized in the other fragments. This could be due to a different stability between the two triplexes. In this regard, the fragments that account for Scheme 2a are quantitatively much more abundant than 4A, 9A and 10A. Loop b could also induce *nt* around position 87 to be highly distorted, thus switching the priority of nuclease activity, or influence the triplex in some other ways.

The presence of more than one configuration could be a result of the DNA being at two different superhelical densities (24), but an equilibrium between the two configurations is also possible (21). The fact that we did not see a family of different triplexes, each one giving rise to a set of fragments, indicates that the whole polyR·polyY sequence, rather than short stretches of mirror symmetry, participated in attaining a minimum energy state. In fragments 11A, 12A, and 13A, cleavages were located at G24 and G25 (Fig. 7b). Due to the dimension of the sequencing gel and the distance of these bands from the reference ladder, it is possible that these cleavages coincide with A28–G29. The facts that the nuclease activity was limited to the polyR·polyY sequence and that, except for the weak fragment 8A (Fig. 7b and Scheme 2), there were no additional fragments or 'consistently cut sites' mapping at loop a, suggest that there were no single-stranded bases other than the purines G14–A54.

The *nt* from 77 to 100 contain a 12-bp direct repeat (GAA-GAGGAGGAA). We noticed a ladder in some of the pyrimidine lanes at these *nt* (Fig. 6b, lanes 7, 9, 11 and 13), but we do not know whether these two direct repeats can alternatively be

involved in the triplex. Configurations involving two loops are, therefore, speculative. The lack of 'consistently cut sites' at the purines around position 40 seems to exclude a triplex-duplex junction in that region. In the configurations we have been discussing, the 5' portion of the purine strand is single-stranded, while the 3' half is engaged in the triplex. In the reverse configuration, the 3' half of the purine strand would be partly single-stranded and partly double-stranded at loop b. In Fig. 6b no single-stranded fragments were observed 3' of A91. A 41-*nt*-long ladder comprising, for example, purines G121–A78, was also not seen. Loop b would have allowed this ladder to comigrate with some of the fragments on the native gel, thus appearing on the sequencing gel 6b as it was for Fig. 6a (lanes 13–14). Although these arguments are against a reverse configuration, this might still be possible. None of the other biased sequences in pBR-MT or M13mt1 were sensitive to *MBN*. In Scheme 2a the triplex is brought very close to a (TG)₅, a sequence that can adopt a *Z*-DNA conformation. Association of a polyR·polyY with *Z*-DNA forming sequences or short direct repeats has been reported for several genes (18,22,38,49–52), at least in one event of unequal sister chromatid exchange (27) and in gene conversion events (53).

CONCLUSION

In this paper we describe our approach to the study of a structure adopted by a polyR·polyY sequence present in the promoter region of the mouse metallothionein-I gene. The data support the formation of an *intramolecular* triplex. The possibility of multiple configurations and a plausible scheme for hydrogen bonding shall guide in designing further experiments to better characterize the structural features and to search for its possible functional role.

ACKNOWLEDGMENTS

We thank Richard Palmiter for providing the metallothionein gene; Barbara Birshtein, Johanna Griffin, Kenneth Breslauer, Robert Wells, William Bauer, Howard Federoff and our colleagues for helpful discussions; Charles Giardina for reading the manuscript; Giovanni Gaudino for assistance. This work was supported by the Grants from the National Institute of Health (GM 28057) and National Science Foundation (DBM 8703990) to F.Y.-H.Wu at SUNY at Stony Brook.

REFERENCES

1. Felsenfeld, G., Davies, R.D. and Rich, A. (1957) *J. Amer. Chem. Soc.*, **79**, 2023–2024.
2. Rich, A. (1958) *Nature*, **181**, 521–525.
3. Lipsett, M.N. (1964) *J. Biol. Chem.*, **239**, 1256–1260.
4. Miles, H.T. and Frazier, J. (1964) *Biochem. Biophys. Res. Commun.*, **14**, 21–28.
5. Miles, H.T. and Frazier, J. (1964) *Biochem. Biophys. Res. Commun.*, **14**, 129–136.
6. Howard, F.B., Frazier, J., Lipsett, M.N. and Miles, H.T. (1964) *Biochem. Biophys. Res. Commun.*, **17**, 93–102.
7. Miller, J.H. and Sobell, H.M. (1966) *Proc. Natl. Acad. Sci. USA*, **55**, 1201–1205.
8. Morgan, A.R. and Wells, R.D. (1968) *J. Mol. Biol.*, **37**, 63–80.
9. Arnott, S. and Bond, P.J. (1973) *Nature New Biol.*, **244**, 99–101.
10. Arnott, S. and Bond, P.J. (1973) *Science*, **181**, 68–69.
11. Arnott, S. and Selsing, E. (1974) *J. Mol. Biol.*, **88**, 509–521.
12. Arnott, S., Bond, P.J., Selsing, E. and Smith, P.J.C. (1976) *Nucleic Acids Res.*, **3**, 2459–2470.

13. Lee, J.S., Johnson, D.A. and Morgan, A.R. (1979) *Nucleic Acids Res.*, **6**, 3073–3091.
14. Antao, V.P., Gray, D.M. and Ratliff, R.L. (1988) *Nucleic Acids Res.*, **16**, 719–738.
15. De los Santos, C., Rosen, M. and Patel, D. (1989) *Biochemistry*, **28**, 7282–7289.
16. Rajagopal, P. and Feigon, J. (1989) *Nature*, **339**, 637–640.
17. Rajagopal, P. and Feigon, J. (1989) *Biochemistry*, **28**, 7859–7870.
18. Caddle, M.S., Lussier, R.H. and Heintz, N.H. (1990) *J. Mol. Biol.*, **211**, 19–33.
19. Christophe, D., Cabrer, B., Bacolla, A., Targovnik, H., Pohl, V. and Vassart, G. (1985) *Nucleic Acids Res.*, **13**, 5127–5144.
20. Hanvey, J.C., Shimizu, M. and Wells, R.D. (1988) *Proc. Natl. Acad. Sci. Usa*, **85**, 6292–6296.
21. Hanvey, J.C., Shimizu, M. and Wells, R.D. (1989) *J. Biol. Chem.*, **264**, 5950–5956.
22. Htun, H. and Dahlberg, J.E. (1988) *Science*, **241**, 1791–1796.
23. Htun, H. and Dahlberg, J.E. (1989) *Science*, **243**, 1571–1576.
24. Johnston, B.H. (1988) *Science*, **241**, 1800–1804.
25. Usdin, K. and Furano, A.V. (1989) *J. Biol. Chem.*, **264**, 15681–15687.
26. Voloshin, O.N., Mirkin, S.M., Lyamichev, V.I., Belotserkovskii, B.P. and Frank-Kamenetskii, M.D. (1988) *Nature*, **333**, 475–476.
27. Weinreb, A., Collier, D.A., Birshtein, B.K. and Wells, R.D. (1990) *J. Biol. Chem.*, **265**, 1352–1359.
28. Wells, R.D., Collier, D.A., Hanvey, J.C., Shimizu, M. and Wohlrab, F. (1988) *FASEB J.*, **2**, 2939–2949.
29. Hanvey, J.C., Klysik, J. and Wells, R.D. (1988) *J. Biol. Chem.*, **263**, 7386–7396.
30. Kroeker, W.D. and Kowalski, D. (1978) *Biochemistry*, **17**, 3236–3243.
31. Baumann, U., Frank, R. and Blöcker, H. (1986) *Eur. J. Biochem.*, **161**, 409–413.
32. Greene, J.R. and Guarente, L. (1987) *Methods Enzymol.*, **152**, 512–522.
33. Cobianchi, F. and Wilson, S.H. (1987) *Methods Enzymol.*, **152**, 94–110.
34. Miller, H. (1987) *Methods Enzymol.*, **152**, 145–170.
35. Fritz, H.-J. (1985) In Glover, D.M. (ed.), *DNA Cloning—A Practical Approach*. IRL Press, Oxford, Vol. I, pp. 151–163.
36. Maniatis, T., Fritsch, E.F. and Sambrook, J. (1982) *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
37. Zoller, M.J. and Smith, M. (1987) *Methods Enzymol.*, **154**, 329–350.
38. Kohwi, Y. (1989) *Nucleic Acids Res.*, **17**, 4493–4502.
39. Shehee, W.R., Loeb, D.D., Adey, N.B., Burton, F.H., Cavasant, N.C., Cole, P., Davies, C.J., McGraw, R.A., Schichman, S.A., Severynse, D.M., Voliva, C.F., Weyter, F.W., Wisely, G.B., Edgell, M.H. and Hutchison III, C.A. (1989) *J. Mol. Biol.*, **205**, 41–62.
40. Glanville, N., Durnam, D.M. and Palmiter, R.D. (1981) *Nature*, **292**, 267–269.
41. Côté, J., Renaud, J. and Ruiz-Carrillo, A. (1989) *J. Biol. Chem.*, **264**, 3301–3310.
42. Margot, J.B., Demers, G.W. and Hardison, R.C. (1989) *J. Mol. Biol.*, **205**, 15–40.
43. Weintraub, H. (1983) *Cell*, **32**, 1191–1203.
44. Moser, H.E. and Dervan, P.B. (1987) *Science*, **238**, 645–650.
45. Cantor, C.R. and Schimmel, P.R. (1980) *Biophysical Chemistry Part I: The Conformation of Biological Macromolecules*. Freeman, W.H. and Company, New York, U.S.A., pp. 328–337.
46. Sheardy, R.D. and Winkle, S.A. (1989) *Biochemistry*, **28**, 720–725.
47. Saenger, W. (1984) *Principles of Nucleic Acid Structure*. Springer-Verlag, New York.
48. Nussinov, R., Shapiro, B., Lipkin, L.E. and Maizel Jr., J.V. (1984) *J. Mol. Biol.*, **177**, 591–607.
49. Mace, H.A.F., Pelham, H.R.B. and Travers, A.A. (1983) *Nature*, **304**, 555–557.
50. Lyamichev, V.I., Mirkin, S.M. and Frank-Kamenetskii, M.D. (1987) *J. Biomol. Struct. Dyn.*, **5**, 275–282.
51. Johnson, A.C., Jinno, Y. and Merlino, G.T. (1988) *Mol. Cell. Biol.*, **8**, 4174–4184.
52. Lichtler, A., Stover, M.L., Angilly, J., Kream, B. and Rowe, D.W. (1989) *J. Biol. Chem.*, **264**, 3072–3077.
53. Fitch, D.H.A., Mainone, C., Goodman, M. and Slightom, J.L. (1990) *J. Biol. Chem.*, **265**, 781–793.